Skip to main content
Erschienen in: Neurosurgical Review 2/2014

01.04.2014 | Original Article

Invasive adenoma and pituitary carcinoma: a SEER database analysis

verfasst von: Tara M. Hansen, Sachin Batra, Michael Lim, Gary L. Gallia, Peter C. Burger, Roberto Salvatori, Gary Wand, Alfredo Quinones-Hinojosa, Lawrence Kleinberg, Kristin J. Redmond

Erschienen in: Neurosurgical Review | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until identification of metastases. Optimal management and survival outcomes for both are not clearly defined. The purpose of this study is to use the Surveillance, Epidemiology, and End Results (SEER) database to report patterns of care and compare survival outcomes in a large series of patients with invasive adenomas or pituitary carcinomas. One hundred seventeen patients diagnosed between 1973 and 2008 with pituitary adenomas/adenocarcinomas were included. Eighty-three invasive adenomas and seven pituitary carcinomas were analyzed for survival outcomes. Analyzed prognostic factors included age, sex, race, histology, tumor extent, and treatment. A significant decrease in survival was observed among carcinomas compared to invasive adenomas at 1, 2, and 5 years (p = 0.047, 0.001, and 0.009). Only non-white race, male gender, and age ≥65 were significant negative prognostic factors for invasive adenomas (p = 0.013, 0.033, and <0.001, respectively). There was no survival advantage to radiation therapy in treating adenomas at 5, 10, 20, or 30 years (p = 0.778, 0.960, 0.236, and 0.971). In conclusion, pituitary carcinoma patients exhibit worse overall survival than invasive adenoma patients. This highlights the need for improved diagnostic methods for the sellar phase to allow for potentially more aggressive treatment approaches.
Literatur
1.
Zurück zum Zitat Oruçkaptan HH, Senmevsim O, Ozcan OE, Ozgen T (2000) Pituitary adenomas: results of 684 surgically treated patients and review of the literature. Surg Neurol 53:211–219PubMedCrossRef Oruçkaptan HH, Senmevsim O, Ozcan OE, Ozgen T (2000) Pituitary adenomas: results of 684 surgically treated patients and review of the literature. Surg Neurol 53:211–219PubMedCrossRef
2.
Zurück zum Zitat Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65:733–744PubMedCrossRef Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65:733–744PubMedCrossRef
3.
Zurück zum Zitat Selman WR, Laws ER, Scheithauer BW et al (1986) The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64:402–407PubMedCrossRef Selman WR, Laws ER, Scheithauer BW et al (1986) The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64:402–407PubMedCrossRef
4.
Zurück zum Zitat Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT et al (2005) Pituitary carcinoma: a clinicopathologic review. Neurosurgery 56:1066–1074PubMed Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT et al (2005) Pituitary carcinoma: a clinicopathologic review. Neurosurgery 56:1066–1074PubMed
5.
Zurück zum Zitat Beatriz M, Lopes S, Scheithauer BW et al (2005) Pituitary carcinoma. Endocrine 28:115–121CrossRef Beatriz M, Lopes S, Scheithauer BW et al (2005) Pituitary carcinoma. Endocrine 28:115–121CrossRef
6.
Zurück zum Zitat Chacko G, Chacko AG, Kovacs K et al (2010) The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13:337–344PubMedCrossRef Chacko G, Chacko AG, Kovacs K et al (2010) The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13:337–344PubMedCrossRef
7.
Zurück zum Zitat Hussaini IM, Trotter C, Zhao Y et al (2007) Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol 170:356–365PubMedCentralPubMedCrossRef Hussaini IM, Trotter C, Zhao Y et al (2007) Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol 170:356–365PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Lau Q, Scheithauer B, Kovacs K et al (2010) MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 13:367–379PubMedCrossRef Lau Q, Scheithauer B, Kovacs K et al (2010) MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 13:367–379PubMedCrossRef
9.
Zurück zum Zitat Pernicone PJ, Scheithauer BW, Sebo TJ et al (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804–812PubMedCrossRef Pernicone PJ, Scheithauer BW, Sebo TJ et al (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804–812PubMedCrossRef
10.
Zurück zum Zitat Thapar K, Kovacs K, Scheithauer BW et al (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–107PubMedCrossRef Thapar K, Kovacs K, Scheithauer BW et al (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–107PubMedCrossRef
11.
Zurück zum Zitat Thapar K, Scheithauer BW, Kovacs K et al (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765–771PubMedCrossRef Thapar K, Scheithauer BW, Kovacs K et al (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765–771PubMedCrossRef
13.
Zurück zum Zitat Zada G, Woodmansee WW, Ramkissoon S et al (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336–344PubMedCrossRef Zada G, Woodmansee WW, Ramkissoon S et al (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336–344PubMedCrossRef
14.
Zurück zum Zitat Kaltsas GA, Nomikos P, Kontogeorgos G et al (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90:3089–3099PubMedCrossRef Kaltsas GA, Nomikos P, Kontogeorgos G et al (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90:3089–3099PubMedCrossRef
15.
Zurück zum Zitat Clarke SD, Woo SY, Butler EB et al (1993) Treatment of secretory pituitary adenoma with radiation therapy. Radiology 188:759–763PubMed Clarke SD, Woo SY, Butler EB et al (1993) Treatment of secretory pituitary adenoma with radiation therapy. Radiology 188:759–763PubMed
16.
Zurück zum Zitat Grigsby PW, Simpson JR, Emami BN et al (1988) Prognostic factors and results of surgery and postoperative irradiation in the management of pituitary adenomas. Int J Radiat Oncol Biol Phys 16:1411–1417CrossRef Grigsby PW, Simpson JR, Emami BN et al (1988) Prognostic factors and results of surgery and postoperative irradiation in the management of pituitary adenomas. Int J Radiat Oncol Biol Phys 16:1411–1417CrossRef
17.
Zurück zum Zitat Kovalic JJ, Mazoujian G, McKeel DW et al (1993) Immunohistochemistry as a predictor of clinical outcome in patients given postoperative radiation for subtotally resected pituitary adenomas. J Neurooncol 16:227–232PubMedCrossRef Kovalic JJ, Mazoujian G, McKeel DW et al (1993) Immunohistochemistry as a predictor of clinical outcome in patients given postoperative radiation for subtotally resected pituitary adenomas. J Neurooncol 16:227–232PubMedCrossRef
18.
Zurück zum Zitat Pinchot SN, Sippel R, Chen H (2009) ACTH-producing carcinoma of the pituitary with refractory Cushing's disease and hepatic metastases: a case report and review of the literature. World J Surg Oncol 7:39PubMedCentralPubMedCrossRef Pinchot SN, Sippel R, Chen H (2009) ACTH-producing carcinoma of the pituitary with refractory Cushing's disease and hepatic metastases: a case report and review of the literature. World J Surg Oncol 7:39PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat van der Klaauw AA, Kienitz T, Strasburger CJ et al (2009) Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature. Pituitary 12:57–69PubMedCrossRef van der Klaauw AA, Kienitz T, Strasburger CJ et al (2009) Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature. Pituitary 12:57–69PubMedCrossRef
20.
Zurück zum Zitat Surveillance Epidemiology and End Results Program (2010) SEER*Stat database: incidence - SEER 17 regs research data + Hurricane Katrina impacted Louisiana cases, Nov 2010 sub (1973–2008 varying)-linked to county attributes–total U.S., 1969–2009 counties. Nov edn. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch Surveillance Epidemiology and End Results Program (2010) SEER*Stat database: incidence - SEER 17 regs research data + Hurricane Katrina impacted Louisiana cases, Nov 2010 sub (1973–2008 varying)-linked to county attributes–total U.S., 1969–2009 counties. Nov edn. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch
21.
Zurück zum Zitat Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version 7.0.4 Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version 7.0.4
22.
Zurück zum Zitat StataCorp. 2005. Stata Statistical Software: Release 9. College Station, TX: StataCorp LP 9 StataCorp. 2005. Stata Statistical Software: Release 9. College Station, TX: StataCorp LP 9
23.
Zurück zum Zitat Raverot G, Wierinckx A, Dantony E et al (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95:1708–1716PubMedCrossRef Raverot G, Wierinckx A, Dantony E et al (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95:1708–1716PubMedCrossRef
24.
Zurück zum Zitat Grossman R, Mukherjee D, Chaichana K et al (2010) Complications and death among elderly patients undergoing pituitary tumour surgery. Clin Endocrinol 73:361–368CrossRef Grossman R, Mukherjee D, Chaichana K et al (2010) Complications and death among elderly patients undergoing pituitary tumour surgery. Clin Endocrinol 73:361–368CrossRef
25.
Zurück zum Zitat Benbow SJ, Foy P, Jones B et al (1997) Pituitary tumours presenting in the elderly: management and outcome. Clin Endocrinol 46:657–660CrossRef Benbow SJ, Foy P, Jones B et al (1997) Pituitary tumours presenting in the elderly: management and outcome. Clin Endocrinol 46:657–660CrossRef
26.
Zurück zum Zitat Cohen DL, Bevan JS, Adams CB (1989) The presentation and management of pituitary tumours in the elderly. Age Ageing 18:247–252PubMedCrossRef Cohen DL, Bevan JS, Adams CB (1989) The presentation and management of pituitary tumours in the elderly. Age Ageing 18:247–252PubMedCrossRef
27.
Zurück zum Zitat Rogne SG, Konglund A, Meling TR et al (2009) Intracranial tumor surgery in patients >70 years of age: is clinical practice worthwhile or futile? Acta Neurol Scand 120:288–294PubMedCrossRef Rogne SG, Konglund A, Meling TR et al (2009) Intracranial tumor surgery in patients >70 years of age: is clinical practice worthwhile or futile? Acta Neurol Scand 120:288–294PubMedCrossRef
28.
Zurück zum Zitat Hong J, Ding X, Lu Y (2010) Clinical analysis of 103 elderly patients with pituitary adenomas: transsphenoidal surgery and follow-up. J Clin Neurosci 15:1091–1095CrossRef Hong J, Ding X, Lu Y (2010) Clinical analysis of 103 elderly patients with pituitary adenomas: transsphenoidal surgery and follow-up. J Clin Neurosci 15:1091–1095CrossRef
29.
Zurück zum Zitat Sheehan JM, Douds GL, Hill K, Farace E (2008) Transsphenoidal surgery for pituitary adenoma in elderly patients. Acta Neurochir (Wien) 150:571–574CrossRef Sheehan JM, Douds GL, Hill K, Farace E (2008) Transsphenoidal surgery for pituitary adenoma in elderly patients. Acta Neurochir (Wien) 150:571–574CrossRef
30.
Zurück zum Zitat Delgrange E, Trouillas J, Maiter D et al (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107PubMed Delgrange E, Trouillas J, Maiter D et al (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107PubMed
31.
Zurück zum Zitat Schaller B (2005) Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol Lett 26:152–159PubMed Schaller B (2005) Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol Lett 26:152–159PubMed
32.
Zurück zum Zitat Schaller B (2003) Gender-related differences in non-functioning pituitary adenomas. Neuro Endocrinol Lett 24:425–430PubMed Schaller B (2003) Gender-related differences in non-functioning pituitary adenomas. Neuro Endocrinol Lett 24:425–430PubMed
33.
Zurück zum Zitat Dudziak K, Honegger J, Bornemann A et al (2011) Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course—case report and review of the literature. J Clin Endocrinol Metab 96:2665–2669PubMedCrossRef Dudziak K, Honegger J, Bornemann A et al (2011) Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course—case report and review of the literature. J Clin Endocrinol Metab 96:2665–2669PubMedCrossRef
Metadaten
Titel
Invasive adenoma and pituitary carcinoma: a SEER database analysis
verfasst von
Tara M. Hansen
Sachin Batra
Michael Lim
Gary L. Gallia
Peter C. Burger
Roberto Salvatori
Gary Wand
Alfredo Quinones-Hinojosa
Lawrence Kleinberg
Kristin J. Redmond
Publikationsdatum
01.04.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Neurosurgical Review / Ausgabe 2/2014
Print ISSN: 0344-5607
Elektronische ISSN: 1437-2320
DOI
https://doi.org/10.1007/s10143-014-0525-y

Weitere Artikel der Ausgabe 2/2014

Neurosurgical Review 2/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.